Immunicon Corporation, Huntingdon Valley, PA is developing and commercializing diagnostic and research products for rare cell analysis and molecular research, with an initial focus on cancer. Immunicon’s instruments and reagents are used to capture, count and characterize rare cells including circulating tumor cells (CTCs) in cancer patients or circulating endothelial cells (CECs), which are elevated in a variety of diseases. The company's goal is to be the leader in the development and commercialization of specialized cellular analysis products that deliver high clinical impact for use in human diagnostics, life science research and pharmaceutical development